$NAGE News

Aging Cell Publishes Study In 'Aging Cell' Showing Niagen NR Supplementation Reduces Muscle Biological Aging and Supports Healthy Muscle Function

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program - Slideshow

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia Telangiectasia

Niagen Bioscience Files Prospectus To Offer And Sell Common Stock Up To $50M

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience Launches NAD Pharmaceuticals, Its Wholly Owned Subsidiary Focused On Developing Therapies For Accelerated Aging And Rare Genetic Diseases

Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications

Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall

Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower

HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives

Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus?